StockData
Addex Therapeutics Ltd. logo

Addex Therapeutics Ltd. (ADXN) stock

ADXNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on May 15, 2026Score 0/30
$3.06−0.44 (-12.57%)

Close on Nov 18, 2026Market cap $62.83KP/E –Yield –

Addex Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

For fiscal 2025 it was -CHF 2.17M. The highest annual figure on record is CHF 1.75M in fiscal 2018.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-CHF 2.17M–
FY2024Dec 31, 2024-CHF 5.37M–
FY2023Dec 31, 2023-CHF 7.99M–
FY2022Dec 31, 2022-CHF 16.44M–
FY2021Dec 31, 2021-CHF 14.71M–
FY2020Dec 31, 2020-CHF 12.18M–
FY2019Dec 31, 2019-CHF 9.48M-641.3%
FY2018Dec 31, 2018CHF 1.75M–
FY2017Dec 31, 2017-CHF 2.14M–

More Addex Therapeutics figures

See a number that looks wrong?